Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US

BMC Gastroenterology

Paul M. Griffin¹  Nathaniel D. Bastian²  Sai Zhang² 

[1] School of Industrial and Systems Engineering, Georgia Institute of Technology, 755 Ferst Dr, Atlanta 30332-0205, GA, USA;Department of Industrial Engineering, Penn State University, University Park 16803, PA, USA

关键词: Chronic hepatitis C;    Viekira Pak;    Olysio;    Harvoni;    Sofosbuvir;    Markov model;    Cost-effectiveness;   

Others  :  1224255
DOI  :  10.1186/s12876-015-0320-4

 received in 2015-01-12, accepted in 2015-07-16,  发布年份 2015

【 摘 要 】

Background

The standard care of treatment of interferon plus ribavirin (plus protease inhibitor for genotype 1) are effective in 50 % to 70 % of patients with CHC. Several new treatments including Harvoni, Olysio + Sovaldi, Viekira Pak, Sofosbuvir-based regimens characterized with potent inhibitors have been approved by the Food and Drug Administration (FDA) providing more options for CHC patients. Trials have shown that the new treatments increased the rate to 80 % to 95 %, though with a substantial increase in cost. In particular, current market pricing of a 12-week course of sofosbuvir is approximately US$84,000. We determine the cost-effectiveness of new treatments in comparison with the standard care of treatments.

Methods

A Markov simulation model of CHC disease progression is used to evaluate the cost-effectiveness of different treatment strategies based on genotype. The model calculates the expected lifetime medical costs and quality adjusted life years (QALYs) of hypothetical cohorts of identical patients receiving certain treatments. For genotype 1, we compare: (1) peginterferon + ribavirin + telaprevir for 12 weeks, followed by 12 or 24 weeks treatment of peginterferon + ribavirin dependent on HCV RNA level at week 12; (2) Harvoni treatment, 12 weeks; (3) Olysio + Sovaldi, 12 weeks for patients without cirrhosis, 24 weeks for patients with cirrhosis; (4) Viekira Pak + ribavirin, 12 weeks for patients without cirrhosis, 24 weeks for patients with cirrhosis; (5) sofosbuvir + peginterferon + ribavirin, 12 weeks for patients with or without cirrhosis. For genotypes 2 and 3, treatment strategies include: (1) peginterferon + ribavirin, 24 weeks for treatment-naïve patients; (2) sofosbuvir + ribavirin, 12 weeks for patients with genotype 2, 24 weeks for genotype 3; (3) peginterferon + ribavirin as initial treatment, 24 weeks for patients with genotype 2/3, follow-up treatment with sofosbuvir + ribavirin for 12/16 weeks are performed on non-responders and relapsers.

Results

Viekira Pak is cost-effective for genotype 1 patients without cirrhosis, whereas Harvoni is cost-effective for genotype 1 patients with cirrhosis. Sofosbuvir-based treatments for genotype 1 in general are not cost-effective due to its substantial high costs. Two-phase treatments with 12-week and 16-week follow-ups are cost-effective for genotype 3 patients and for genotype 2 patients with cirrhosis. The results were shown to be robust over a broad range of parameter values through sensitivity analysis.

Conclusions

For genotype 1, sofosbuvir-based treatments are not cost-effective compared to Viekira Pak and Harvoni, although a 30 % reduction in sofosbuvir price would change this result. Sofosbuvir + ribavirin are cost-effective as second-phase treatments following peginterferon + ribavirin initial treatment for genotypes 2 and 3. However, there is limited data on sofosbuvir-involved treatment, and the results obtained in this study must be interpreted within the model assumptions.

【 授权许可】

   
2015 Zhang et al.

【 图 表 】

Fig. 1.

【 参考文献 】

• [1]Verna EC, Brown RS Jr: Hepatitis C virus and liver transplantation. Clin Liver Dis 2006, 10:919-940.
• [2]Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology, 2004;39(4):1147–71.
• [3]Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C: Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology 2010, 51:1176-84.
• [4]Averhoff FM, Glass N, Holtzman D: Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis 2012, 55(Suppl 1):S10-5.
• [5]Chen SL, Morgan TR: The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006, 3:47-52.
• [6]Sullivan SD, Jensen M, Bernstein DE, Hassanein TI, Foster GR, Lee SS, Cheinquer H, Craxi A, Cooksley G, Klaskala W, Perttit K, Patel KK, Green J: Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Am J Gastroenterol 2004, 99:1490-96.
• [7]Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology. 2006;43(6):1303–10.
• [8]Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335–74.
• [9]Petta S, Cabibbo G, Enea M, Macaluso FS, Plaia A, Bruno R, et al. Cost-Effectiveness of Sofosbuvir-Based Triple Therapy for Untreated Patients with Genotype 1 Chronic Hepatitis C. Hepatology. 2014;59(5):1692–705.
• [10]Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405–16.
• [11]Tucker M. FDA approves 'game changer' hepatitis C drug Sofosbuvir". Medscape. December 6, 2013. http://www.medscape.com/viewarticle/817371 (accessed 1 March 2015).
• [12]Ledipasvir-Sofosbuvir (Harvoni). Hepatitis C Online. http://www.hepatitisc.uw.edu/page/ledipasvir-sofosbuvir (accessed 1 Mar 2015).
• [13]Simeprevir (Olysio). Hepatitis C Online. http://www.hepatitisc.uw.edu/page/treatment/drugs/simeprevir-drug (accessed 1 Mar 2015).
• [14]Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir (Viekira Pak). Hepatitis C Online. http://www.hepatitisc.uw.edu/page/treatment/drugs/3d (accessed 1 Mar 2015).
• [15]Salomon JA, Weinstein MC, Hammitt JK: Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003, 290:228-37.
• [16]Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Al-Assi MT, Subramanian GM, An D, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Pianko S, Nelson DR: Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013, 368:1867-77.
• [17]Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ: Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013, 368:1878-87.
• [18]Sovaldi drug description. www.rxlist.com/sovaldi-drug.htm. (accessed 1 Mar 2015).
• [19]7U.S. Food and Drug Administration Approves Gilead’s Sovaldi™ (Sofosbuvir) for the Treatment of Chronic Hepatitis C. Gilead [eLetter] 6 December 2013. www.gilead.com/news/press-releases/2013/12/us-food-and-drug-administration-approves-gileads-sovaldi-sofosbuvir-for-the-treatment-of-chronic-hepatitis-c#sthash.T9uTbSWK.dpuf". (accessed 1 March 2015).
• [20]Peginterferon alfa-2a (Pegasys). Hepatitis C Online. www.hepatitisc.uw.edu/page/treatment/drugs/peginterferon-alfa-drug. (accessed 1 March 2015).
• [21]Liu S, Watcha D, Holodniy M, Goldhaber-Fiebert J: Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations. Ann Intern Med 2014, 161:546-53.
• [22]Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL: Estimates of the cost-effective of a single course of interferon-alpha2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997, 127:855-65.
• [23]Davis GL, Alter MJ, El-Serag H, Poynard R, Jennings LW: Aging of the hepatitis C virus infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010, 138:513-21.
• [24]Kim WR, Poterucha JJ, Hermans JE, Therneau TM, Dickson ER, Evans RW, Gross JB: Cost-effectiveness of 6 and 48 weeks of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med 1997, 127:866-74.
• [25]Younossi Z, Singer M, Mchutchison J, Shermock K: Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999, 30:1318-24.
• [26]E Arias. United States Life Tables, 2008. National Vital Statistics Reports. 2012;61. www.cdc.gov/nchs/data/nvsr/nvsr59/nvsr59_10.pdf. (accesses 1 March 2015).
• [27]Younossi Z, McCormick M, Boparai N, Price L, Fqrquhar L, Guyatt G: Assessment of utilities and health-related quality of life in patients with chronic liver disease. Gatroenterology 1999, 116:A1292.
• [28]Bureau of Labor Statistics. http://data.bls.gov/timeseries/CUUR0000SAM?output_view=pct_12mths (accessed 1 Mar 2015).
• [29]Fattovich G, Guistina G, Degas E: Morbidity and mortality in compensated cirrhosis type C: a retrospective follow up study of 384 patients. Gastroenterology 1997, 112:463-72.
• [30]Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C, Trinchet JC, Beaugrand M, Chevret S: Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000, 47:131-36.
• [31]Fattovich G, Stroffolini T, Zagni I, Donato F: Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004, 127:S35-50.
• [32]Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR: The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002, 122:889-96.